Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML
UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.
Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma
Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.
Future CRC Treatment to Focus on Mutation Status, Expert Says
Tanios S. Bekaii-Saab, MD, gave an overview of colorectal cancer along with current standard of care, and potential treatment options.
JAK Inhibitors, Mutations, and Transplantation in Myelofibrosis Management
John O. Mascarenhas, MD, led a panel discussion on myelofibrosis management including the use of JAK inhibitors and transplantation.
Don’t Be Afraid to Ask Questions Along the Bladder Cancer Journey, Patients and Clinicians Advise
A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.
Selecting and Sequencing Ruxolitinib, Other Treatments in Chronic GVHD
Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.
Lenvatinib Plus Pembrolizumab Yields Continuous Efficacy in CLEAR Trial for Advanced RCC
Brian I. Rini, MD, led a panel where he and his colleagues discussed the results of the CLEAR trial and its implications in renal cell carcinoma.
